Table 1

Baseline Characteristics of Patients

Total Population (n = 1,391)ZES Resolute (n = 697)EES Xience V (n = 694)p Value
Age (yrs)64.2 ± 10.8 (1,391)63.9 ± 10.9 (697)64.5 ± 10.7 (694)0.32
Men1,009/1,391 (72.5)505/697 (72.5)504/694 (72.6)0.94
BMI (kg/m2)27.7 ± 4.0 (1,391)27.7 ± 3.9 (697)27.8 ± 4.0 (694)0.57
Diabetes mellitus (any)301/1,391 (21.6)158/697 (22.7)143/694 (20.6)0.35
Chronic renal failure38/1,391 (2.7)19/697 (2.7)19/694 (2.7)0.99
Arterial hypertension773/1,391 (55.6)386/697 (55.4)387/694 (55.8)0.89
Hypercholesterolemia803/1,357 (59.2)392/688 (57.0)411/669 (61.4)0.10
Current smoker340/1,391 (24.4)176/697 (25.3)164/694 (23.6)0.48
Family history of CAD740/1,391 (53.2)370/697 (53.1)370/694 (53.3)0.93
MI (any)450/1,391 (32.4)213/697 (30.6)237/694 (34.1)0.15
Previous PCI288/1,391 (20.7)139/697 (19.9)149/694 (21.5)0.48
Previous CABG148/1,391 (10.6)68/697 (9.8)80/694 (11.5)0.28
PCI for acute coronary syndrome717/1,391 (51.5)362/697 (51.9)355/694 (51.2)0.77
Clinical indication0.47
 Stable angina pectoris674/1,391 (48.5)335/697 (48.1)339/694 (48.8)
 Unstable angina325/1,391 (23.4)172/697 (24.7)153/694 (22.0)
 Non–ST-segment elevation MI392/1,391 (28.2)190/697 (27.3)202/694 (29.1)
Left ventricular ejection fraction <30%32/1,051 (3.0)19/529 (3.6)13/522 (2.5)0.30
Multivessel treatment336/1,391 (24.2)174/697 (25.0)162/694 (23.3)0.48
Total no. of lesions treated/patient0.49
 1 lesion treated857/1,391 (61.6)422/697 (60.5)434/694 (62.7)
 2 lesions treated393/1,391 (28.3)198/697 (28.4)195/694 (28.1)
 3 of more lesions treated141/1,391 (10.1)77/697 (11.0)64/694 (9.2)
De novo coronary lesions only1,287/1,391 (92.5)644/697 (92.4)643/694 (92.7)0.86
At least 1 CTO95/1,391 (6.8)51/697 (7.3)44/694 (6.3)0.47
At least 1 bifurcation362/1,391 (26.0)179/697 (25.7)183/694 (26.4)0.77
At least 1 bifurcation with side branch treatment213/1,391 (15.3)98/697 (14.1)115/694 (16.6)0.19
At least 1 in-stent restenosis69/1,391 (5.0)36/697 (5.2)33/694 (4.8)0.73
At least 1 small-vessel (RVD <2.75 mm)874/1,391 (62.8)445/697 (63.8)429/694 (61.8)0.43
At least 1 lesion length >27 mm293/1,391 (21.1)156/697 (22.4)137/694 (19.7)0.23
Glycoprotein IIb/IIIa antagonist use193/1,391 (13.9)90/697 (12.9)103/694 (14.8)0.29
At least 1 off-label indication§1,077/1,391 (77.4)547/697 (78.5)530/694 (76.4)0.35

Values are mean ± SD (n) or n/N (%).

BMI = body mass index; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CTO = chronic total occlusion; EES = everolimus-eluting stent(s); PCI = percutaneous coronary intervention; RVD = reference vessel diameter; ZES = zotarolimus-eluting stent(s).

  • Chronic renal failure defined by serum creatinine level ≥130 μmol/l.

  • Left ventricular ejection fraction assessed with ultrasound, magnetic resonance imaging, or left ventricular angiography.

  • Including chronic total occlusion but not grafts and in-stent restenosis.

  • § Off-label stent use includes renal insufficiency, an ejection fraction of <30%, the occurrence of acute myocardial infarction (MI) within the previous 72 h, more than 1 lesion/vessel, at least 2 vessels with stents, a lesion measuring more than 27 mm, bifurcation, bypass grafts, in-stent restenosis, unprotected left main artery, lesions with thrombus, or total occlusion.